Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-01-23 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
SFX-01 featured in Nature Reviews Drug Discovery
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content describes a company announcement regarding its lead product being featured in a prestigious scientific journal ('Nature Reviews Drug Discovery') and includes commentary from the CEO. This type of general, immediate corporate news update that doesn't fit specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or announcement. Given the explicit 'RNS Number' and the nature of the announcement, the 'Regulatory Filings' code (RNS) is the most appropriate classification.
2019-01-23 English
Change of Adviser
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number (6863N) and the header 'RNS Number : 6863N', indicating it is a regulatory news service announcement from the London Stock Exchange. The content announces a 'Change of Adviser' (appointment of finnCap Ltd as Nominated Adviser and Joint Broker). This type of corporate action announcement, which is not a financial report (like 10-K or IR), nor a director's dealing (DIRS), nor a dividend notice (DIV), fits best under the general category for regulatory announcements that do not have a more specific code. Since it is a formal regulatory announcement distributed via RNS, and it doesn't fit definitions like MANG (Board/Management Change) or CAP (Financing Update) perfectly, the most appropriate fallback is Regulatory Filings (RNS), as it is explicitly an RNS release.
2019-01-22 English
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Earnings Release Classification · 1% confidence The document is a press release announcing 'top-line data' from a clinical pharmacology trial for a drug candidate (ensifentrine) used for COPD. It details study results (primary and secondary endpoints), includes quotes from the CEO and a medical expert, and explicitly mentions that the company will host an 'investment community conference call' to discuss the data. This structure—announcing key results and scheduling an investor call—is characteristic of an Earnings Release (ER) or a similar material event disclosure. Since the content is focused on releasing preliminary financial/clinical performance data rather than a full quarterly report (IR) or a transcript (CT), 'ER' is the most appropriate classification. The document is not a short announcement linking to a report, but the report/data summary itself. Q1 2019
2019-01-14 English
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
Regulatory Filings Classification · 1% confidence The document is a press release dated January 9, 2019, announcing that the World Health Organization (WHO) approved 'ensifentrine' as the International Non-proprietary Name (INN) for Verona Pharma's drug candidate RPL554. It discusses clinical trial progress, mechanism of action, and future development plans. This type of announcement, which communicates significant operational or product development news via a press release format, typically falls under a general regulatory announcement or an earnings-related communication if it were timed with results. Since it is not a full financial report (10-K, IR), a specific management discussion (MDA), or a formal earnings release (ER) detailing period results, and it is not a proxy statement (DEF 14A) or a capital change (CAP/SHA), the most appropriate classification is a general Regulatory Filing (RNS) as it is a formal, time-sensitive announcement to the market about a key corporate/product milestone. It is not short enough to definitively be an RPA, and it contains substantial narrative content.
2019-01-09 English
Nuvec licence extension
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details a specific corporate action: the extension of a license agreement for their Nuvec® technology, including strategic implications for cancer treatments and dual therapy approaches. This is a material corporate event announcement, not a full financial report (like 10-K or IR), a management discussion (MDA), or a formal presentation (IP). Since it is a general regulatory announcement distributed through RNS that doesn't fit into more specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category.
2018-12-20 English
Share option exercise and issue of equity
Share Issue/Capital Change Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content details the exercise of share options and the subsequent issuance of 78,918 new ordinary shares, along with the resulting total number of voting rights. This action directly relates to changes in the company's share capital structure. While it involves share issuance (related to SHA), the primary nature of this specific announcement, originating from RNS and detailing a corporate action that affects the share count, fits best under the general 'Regulatory Filings' category (RNS) or potentially 'Share Issue/Capital Change' (SHA). Given the explicit RNS header and the nature of the disclosure (a mandatory notification of share issuance/voting rights change), RNS is a strong candidate. However, since the core event is the issuance of new shares following option exercises, 'SHA' (Share Issue/Capital Change) is more specific to the substance than the general 'RNS' fallback. The document is short and is a direct announcement, not a report itself. I will classify it as SHA because it explicitly details the issuance of new shares and the resulting total voting rights, which is a capital change event.
2018-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.